A carregar...
Efficacy and Safety of Ruxolitinib in the Treatment of Patients with Myelofibrosis
The JAK 1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-ABL1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival. In Phase III clinical studies, ruxolitinib provided rapid and durable improvement of myelofibro...
Na minha lista:
| Publicado no: | Future Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4920055/ https://ncbi.nlm.nih.gov/pubmed/25757677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.272 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|